Table 2.
Data analysis of all assay results of the caudate and putamen of the ten AD cases chosen for BACE1 mRNA analysis and age‐matched controls. A p value of <0.05 was considered significant: * indicates p < 0.05, ** indicates p< 0.01, **** indicates p < 0.0001, vs. the controls.
| Assays | Caudate | Putamen | ||
|---|---|---|---|---|
| Mean ± SME | p value | Mean ± SME | p value | |
| 8‐oxo‐dG (pg/μg total DNA) | ||||
| Control | 20.67 ± 2.581 | 16.59 ± 1.928 | ||
| AD | 26.49 ± 7.545 | ˃ 0.05 | 14.17 ± 0.823 | ˃ 0.05 |
| 8‐oxo‐G (pg/μg total DNA) | ||||
| Control | 33.08 ± 4.313 | 48.41 ± 6.115 | ||
| AD | 22.07 ± 1.838* | 0.0376 | 37.46 ± 4.851 | ˃ 0.05 |
| Dopamine (ng/g wet wt) | ||||
| Control | 19.29 ± 6.986 | 17.21 ± 5.083 | ||
| AD | 29.66 ± 9.108 | ˃ 0.05 | 25.89 ± 4.060 | ˃ 0.05 |
| VMAT2 Density (fmol/mg) | ||||
| Control | 133.5 ± 10.28 | 123.4 ± 10.62 | ||
| AD | 176.6 ± 17.08 | 0.051 | 152.5 ± 18.34 | ˃ 0.05 |
| D1 Receptor Density (fmol/mg) | ||||
| Control | 25.28 ± 3.410 | 24.63 ± 3.318 | ||
| AD | 43.98 ± 1.292**** | < 0.0001 | 40.38 ± 2.904** | 0.0030 |
| BACE1 mRNA Levels | ||||
| Control | 2.804 ± 0.1252 | 2.664 ± 0.092 | ||
| AD | 2.948 ± 0.1615 | ˃ 0.05 | 3.025 ± 0.101* | 0.0197 |
AD, Alzheimer's disease; BACE1, β‐site APP cleaving enzyme 1; 8‐oxo‐dG, 8‐oxo‐7,8‐dihydro‐2'‐deoxyguanosine; 8‐oxo‐G, 8‐oxo‐7,8‐dihydroguanosine; VMAT2, vesicular monoamine transporter 2 densities.